Navigation Links
1 step back ... 2 steps forward
Date:9/5/2008

Washington, DCWomen with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposiummay change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.

The strategy being investigated involves breast cancers that are fueled by estrogenthese are called estrogen-receptor or progesterone-receptor positive cancers (ER or PR positive). Women who have ER or PR positive metastatic breast cancer often take anti-hormonal medicines, such as aromatase inhibitors, to keep the cancer from progressing. Aromatase inhibitors lower the amount of estrogen in the body. Over time, however, the cancer becomes resistant to this approach and begins to grow.

"At first, the tumor's growth is halted because the aromatase inhibitor is depriving the cancer of the estrogen it needs to grow," says Claudine Isaacs, M.D., clinical director of breast cancer program at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center. "Eventually, though, the cancer will figure out another way to thrive in the absence of the estrogen."

Isaacs and her colleagues, including lead author Deepa Subramaniam, M.D. of Lombardi, are conducting a clinical trial to see if a new approach can destroy the machinery the tumor creates in order to grow without the estrogen. The drug being studied is called sorafenib.

The results of the phase II study involving 27 patients were presented today at the ASCO 2008 Breast Cancer Symposium. It included post-menopausal women with metastatic breast cancer whose cancer had recurred or progressed while taking the aromatase inhibitor anastrozole. The preliminary analysis shows a clinical benefit response in 26 percent of the patients taking both sorafenib and anastrozole.

"Given what we know about the ineffectiveness of sorafenib alone in metastatic breast cancer, we believe the benefit that we're seeing may be attributable to the restoration of sensitivity to aromatase inhibitors," Isaacs concludes. "To manage breast cancer long term, it's apparent that we may need to continually switch drugs to keep up with how a cancer evolves and evades each approach. In a sense, for each step back, we hope to take two steps forward."


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
2. On September 7th Local Organizations Partner to Celebrate Healthy Steps
3. Americas Next Top Model Steps up for Psoriasis Awareness
4. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
5. Kmart Steps Out to Fight Diabetes
6. PDHI Launches ConXus Steps to Deliver Online Health Action Plans
7. YMCAs Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During America On the Move Week with the YMCA
8. American Diabetes Association Steps Up to Fight Diabetes
9. Committee to Reduce Infection Deaths Releases 10 Lifesaving Steps to Protect Students from MRSA Infections
10. Six Simple Steps to Protect Against and Stop the Spread of Superbugs
11. Five Steps to Pop the Cork - Not Your Eye Out
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: